- Home
- UWMC vs CVAC Comparison
UWMC vs CVAC Comparison
Compare UWMC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- CVAC
- Stock Information
- Founded
- UWMC 1986
- CVAC 2000
- Country
- UWMC United States
- CVAC Germany
- Employees
- UWMC N/A
- CVAC N/A
- Industry
- UWMC Finance: Consumer Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- UWMC Finance
- CVAC Health Care
- Exchange
- UWMC Nasdaq
- CVAC Nasdaq
- Market Cap
- UWMC 1.4B
- CVAC 1.2B
- IPO Year
- UWMC N/A
- CVAC 2020
- Fundamental
- Price
- UWMC $5.36
- CVAC $5.41
- Analyst Decision
- UWMC Hold
- CVAC Hold
- Analyst Count
- UWMC 8
- CVAC 3
- Target Price
- UWMC $6.32
- CVAC $6.83
- AVG Volume (30 Days)
- UWMC 9.4M
- CVAC 406.8K
- Earning Date
- UWMC 11-06-2025
- CVAC 11-11-2025
- Dividend Yield
- UWMC 7.41%
- CVAC N/A
- EPS Growth
- UWMC 112.84
- CVAC N/A
- EPS
- UWMC 0.07
- CVAC 1.01
- Revenue
- UWMC $2,622,828,000.00
- CVAC $599,540,810.00
- Revenue This Year
- UWMC $11.44
- CVAC N/A
- Revenue Next Year
- UWMC $17.88
- CVAC $23.83
- P/E Ratio
- UWMC $81.39
- CVAC $5.40
- Revenue Growth
- UWMC 13.45
- CVAC 675.15
- 52 Week Low
- UWMC $3.80
- CVAC $2.37
- 52 Week High
- UWMC $7.60
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- UWMC 32.86
- CVAC 54.21
- Support Level
- UWMC $5.28
- CVAC $5.33
- Resistance Level
- UWMC $6.31
- CVAC $5.44
- Average True Range (ATR)
- UWMC 0.26
- CVAC 0.03
- MACD
- UWMC -0.17
- CVAC 0.00
- Stochastic Oscillator
- UWMC 4.68
- CVAC 66.10
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.